Evidence map›Paper›PMID 35198392›Full record

ReviewAsian journal of urology2022

Atypical small acinar proliferation and its significance in pathological reports in modern urological times.

Georgios Tsampoukas, Victor Manolas, Dominic Brown, Athanasios Dellis, Konstantinos Deliveliotis, Mohamad Moussa, Athanasios Papatsoris

Abstract readReview
In one paragraph

Review in Asian journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Expression of nectin-4 in prostate cancer.Northern clinics of Istanbul · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Georgios TsampoukasDepartment of Urology, Princess Alexandra Hospital, Harlow, UK.
Victor ManolasDepartment of Urology, Princess Alexandra Hospital, Harlow, UK.
Dominic BrownDepartment of Urology, Princess Alexandra Hospital, Harlow, UK.
Athanasios DellisU-merge Ltd. (Urology for Emerging Countries), London, UK.
Konstantinos Deliveliotis2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Mohamad MoussaChairman of Surgery & Urology Department, Lebanese University & Zahraa Hospital, University Medical Center, Beirut, Lebanon.
Athanasios PapatsorisU-merge Ltd. (Urology for Emerging Countries), London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical small acinar proliferation is a histopathological diagnosis of unspecified importance in prostate needle-biopsy reports, suggestive but not definitive for cancer. The terminology corresponds to some uncertainty in the biopsy report, as the finding might represent an underlying non-cancerous pathology mimicking cancer or an under-sampled prostate cancer site. Therefore, traditional practice favors an immediate repeat biopsy. However, in modern urological times, the need of urgent repeat biopsy is being challenged by some authors as in the majority of cases, the grade of cancer found in subsequent biopsy is reported to be low or the disease to be non-significant. On the other hand, high risk disease cannot be excluded, whereas no clinical or pathological factors can predict the final outcome. In this review, we discuss the significance of the diagnosis of atypical small acinar proliferation in the biopsy report, commenting on its importance in modern urological practice.

Indexed as

Atypical small cell proliferationGradeLesion suspicious for cancerProstate cancerRepeat biopsySignificant cancer

Identifiers

PMID35198392
PMCPMC8841244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.